BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28034519)

  • 21. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced Age is not a Risk Factor for Mortality in Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Organisms: a Multicenter Cohort Study.
    Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Ito A; Nakashita M; Suzuki M; Kobayashi K; Tsugita M
    Jpn J Infect Dis; 2020 Jul; 73(4):288-292. PubMed ID: 32115542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
    Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
    Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
    Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
    J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
    Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
    Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
    J Infect Dev Ctries; 2009 May; 3(4):285-94. PubMed ID: 19759492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended spectrum AmpC and metallo-beta-lactamases in Serratia and Citrobacter spp. in a disc approximation assay.
    Rizvi M; Fatima N; Rashid M; Shukla I; Malik A; Usman A; Siddiqui S
    J Infect Dev Ctries; 2009 Apr; 3(3):177-86. PubMed ID: 19759472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
    Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.
    Yang K; Guglielmo BJ
    Ann Pharmacother; 2007 Sep; 41(9):1427-35. PubMed ID: 17666573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experiences of bacteremia caused by metallo-beta-lactamase-producing gram-negative organisms.
    Lee NY; Yan JJ; Lee HC; Liu KH; Huang ST; Ko WC
    J Microbiol Immunol Infect; 2004 Dec; 37(6):343-9. PubMed ID: 15599466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
    Santevecchi BA; Smith TT; MacVane SH
    Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of metallo-β-lactamase acquired genes among carbapenems susceptible and resistant Gram-negative clinical isolates using multiplex PCR, Khartoum hospitals, Khartoum Sudan.
    Adam MA; Elhag WI
    BMC Infect Dis; 2018 Dec; 18(1):668. PubMed ID: 30558551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
    Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
    Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
    Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
    J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of noncarbapenem therapy for the treatment of ceftriaxone-resistant Enterobacterales outside the urinary tract.
    Rausch EP; Alby K; Wilson W
    Antimicrob Steward Healthc Epidemiol; 2024; 4(1):e1. PubMed ID: 38234414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three cases of IMP-type metallo-β-lactamase-producing Enterobacter cloacae bloodstream infection in Japan.
    Hamada Y; Watanabe K; Tada T; Mezaki K; Takeuchi S; Shimizu T; Kirikae T; Ohmagari N
    J Infect Chemother; 2013 Oct; 19(5):956-8. PubMed ID: 23160627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.